John Green and Tuberculosis
Episode
45 min
Read time
2 min
Topics
Productivity, Sales & Revenue, Software Development
AI-Generated Summary
Key Takeaways
- ✓Patent Evergreening Mechanics: Drug companies routinely file dozens of secondary patents on existing drugs to extend monopoly protection far beyond the standard 20-year term. A study of the 12 best-selling US drugs found an average of 131 patents each, translating to an average of 38 years of effective patent protection rather than 20.
- ✓India's Section 3D as a Legal Tool: India's patent law requires companies seeking secondary patents on existing drug formulations to prove increased therapeutic efficacy — not just a reformulation. This provision successfully blocked J&J's secondary bedaquiline patent in March 2023, immediately enabling Indian generic manufacturers to produce affordable versions of the drug.
- ✓Strategic Patent Filing Timing: Pharmaceutical companies deliberately delay filing secondary patents to maximize back-end protection. One patent attorney's documented advice instructs companies to wait two to three years during drug discovery before filing add-on patents. J&J waited four years before filing bedaquiline's salt formulation patent, extending their monopoly accordingly.
- ✓Coordinated Advocacy Sequencing: Effective pharmaceutical advocacy requires layering legal challenges, survivor testimony, and mass public pressure in sequence. Tahir Amin's IMAK spent nearly 20 years building India's legal framework; TB survivors Fumesa Tesile and Nandita Venkateshian filed the patent challenge; only then did John Green's audience amplify pressure — producing J&J's policy concession within one week.
- ✓US Patent Policy Has Global Consequences: IMAK shifted 80% of its work to the United States because US patent office practices and World Trade Organization policies shaped by US pharmaceutical companies set global standards. Reforming how the US Patent Office evaluates and grants secondary drug patents would directly affect drug access in low- and middle-income countries worldwide.
What It Covers
Author John Green and journalist Dan Weissman examine how Johnson & Johnson used secondary drug patents to restrict access to bedaquiline, a tuberculosis drug, affecting an estimated 1.4 million patients annually. India's Section 3D patent law, two TB survivors' legal victory, and Green's nerdfighter community combined to pressure J&J into expanding generic access.
Key Questions Answered
- •Patent Evergreening Mechanics: Drug companies routinely file dozens of secondary patents on existing drugs to extend monopoly protection far beyond the standard 20-year term. A study of the 12 best-selling US drugs found an average of 131 patents each, translating to an average of 38 years of effective patent protection rather than 20.
- •India's Section 3D as a Legal Tool: India's patent law requires companies seeking secondary patents on existing drug formulations to prove increased therapeutic efficacy — not just a reformulation. This provision successfully blocked J&J's secondary bedaquiline patent in March 2023, immediately enabling Indian generic manufacturers to produce affordable versions of the drug.
- •Strategic Patent Filing Timing: Pharmaceutical companies deliberately delay filing secondary patents to maximize back-end protection. One patent attorney's documented advice instructs companies to wait two to three years during drug discovery before filing add-on patents. J&J waited four years before filing bedaquiline's salt formulation patent, extending their monopoly accordingly.
- •Coordinated Advocacy Sequencing: Effective pharmaceutical advocacy requires layering legal challenges, survivor testimony, and mass public pressure in sequence. Tahir Amin's IMAK spent nearly 20 years building India's legal framework; TB survivors Fumesa Tesile and Nandita Venkateshian filed the patent challenge; only then did John Green's audience amplify pressure — producing J&J's policy concession within one week.
- •US Patent Policy Has Global Consequences: IMAK shifted 80% of its work to the United States because US patent office practices and World Trade Organization policies shaped by US pharmaceutical companies set global standards. Reforming how the US Patent Office evaluates and grants secondary drug patents would directly affect drug access in low- and middle-income countries worldwide.
Notable Moment
When John Green visited a TB hospital in Sierra Leone, a seemingly energetic nine-year-old boy gave him a full facility tour. Doctors later revealed the child was actually a severely malnourished 16-year-old whose multidrug-resistant TB treatment was failing — and who needed bedaquiline, then completely unavailable in the country.
Episode Transcript
This is Drug Story. I'm Thomas Getz. A few years ago, I wrote a book called The Remedy. It was about tuberculosis, which is the deadliest infectious disease in human history. The bacteria that causes TB was first identified in 1882 by a German physician and researcher named Robert Koch. Koch was an amazing scientist, but quite a flawed human being. This discovery was perhaps the biggest breakthrough in the history of medicine up to that time because tuberculosis was a horrible disease. In The US and other countries, TB was the leading cause of death at the time. More people died of TB than heart disease or cancer or any noninfectious disease. So to finally know what caused TB, a germ. Well, that seemed like the first step towards a cure. Koch's discovery got people hoping that it might be possible to actually vanquish this most deadly disease in human history. And sure enough, a few years after he discovered the bacteria that caused TB, Robert Koch announced that he had also discovered the cure, the remedy. Well, not to spoil the ending of my own book, but in actual fact, Koch's remedy did not work. It was debunked by none other than Arthur Conan Doyle, who was at the time also a doctor and a writer. He had just created a detective character called Sherlock Holmes. This is a crazy story. It's an amazing tale of science and innovation and ego. That's kind of why I wrote a whole book about it. And it's still worth reading, even now that you kind of know the ending. Well, it would actually take more than half a century before a true cure for tuberculosis came along, and that was streptomycin. It was an antibiotic that was discovered in 1943. Streptomycin works. It kills the bacteria that causes TB. And since then, several other antibiotics have been discovered that work even better. Because the thing about TB is it changes. The bacteria adapts to the drugs. It finds a way to evolve around the the antibiotic and keep going. Since Koch's discovery of the bacteria in 1882, more than a billion people have died of the disease. Even with antibiotics, even today, people die of TB. More than a million people a year, in fact. They're mostly in Asia, Africa, and India. These people die even though there are drugs that work, that cure the disease. Well, in today's episode of drug story, I'm actually going to let someone else tell that story. John Green, the author of another book about TB called Everything is Tuberculosis. You may have heard of it. It's been a bestseller for months, and he says some very nice things about my book in there, which I appreciate. So today, I'm handing over drug story to John Green and the excellent journalist Dan Weissman. He's host of the NPR podcast An Arm and a Leg. In this episode of An Arm and a Leg, Dan does …
Get the full transcript (7,639 words) + summary by email — free
One-time email with the complete transcript and AI summary of this episode. No account needed.
One email, no spam. We’ll also show you what SignalCast does.
You just read a 3-minute summary of a 42-minute episode.
Get Drug Story summarized like this every Monday — plus up to 2 more podcasts, free.
Pick Your Podcasts — FreeKeep Reading
Books, tools, and gear mentioned in this episode
SignalCast may earn commission on purchases via these links. As an Amazon Associate, SignalCast earns from qualifying purchases.
Products
“Johnson & Johnson used secondary drug patents to restrict access to bedaquiline, a tuberculosis drug, affecting an estimated 1.4 million patients annually.”
other
“India's Section 3D patent law requires companies seeking secondary patents on existing drug formulations to prove increased therapeutic efficacy — not just a reformulation. This provision successfully blocked J&J's secondary bedaquiline patent in March 2023.”
company
“Author John Green and journalist Dan Weissman examine how Johnson & Johnson used secondary drug patents to restrict access to bedaquiline, a tuberculosis drug, affecting an estimated 1.4 million patients annually.”
More from Drug Story
We summarize every new episode. Want them in your inbox?
Similar Episodes
Related episodes from other podcasts
The Rest is History
Mar 19
653. London’s Golden Age: The Shadow of the Madhouse (Part 4)
The Founders Podcast
Dec 25
The Life of Jesus
The Prof G Pod
Sep 3
The AI Revolution Isn’t What Silicon Valley Promised — with Josh Tyrangiel
Modern Wisdom
Aug 22
Ex-Gang Member: What Makes A Violent Man Change? - Johnny Chang - #1140
The School of Greatness
Jul 10
Why Your Relationship Keeps Repeating the Same Pattern | Gary John Bishop
Explore Related Topics
This podcast is featured in Best Health Podcasts (2026) — ranked and reviewed with AI summaries.
Read this week's Software Engineering Podcast Insights — cross-podcast analysis updated weekly.
You're clearly into Drug Story.
Every Monday, we deliver AI summaries of the latest episodes from Drug Story and 192+ other podcasts. Free for one show.
Start My Monday DigestNo credit card · Unsubscribe anytime